ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.575,79
0,14%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Zai Lab Ltd (ZLAB)

  7. Zai Lab Ltd (ZLAB) News

ZLAB

Zai Lab (ZLAB)

Zai Lab Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ZLAB
DatumZeitQuelleÜberschriftSymbolFirma
22/05/202413h30Business WireZai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque PsoriasisNASDAQ:ZLABZai Lab Ltd
20/05/202406h21Business WireZai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in ChinaNASDAQ:ZLABZai Lab Ltd
16/05/202422h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
16/05/202413h30Business WireZai Lab Announces Participation in May and June Investor ConferencesNASDAQ:ZLABZai Lab Ltd
15/05/202422h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
14/05/202419h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ZLABZai Lab Ltd
14/05/202413h30Business WireZai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in ChinaNASDAQ:ZLABZai Lab Ltd
13/05/202402h20Business WireZai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPANASDAQ:ZLABZai Lab Ltd
08/05/202422h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZLABZai Lab Ltd
08/05/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZLABZai Lab Ltd
08/05/202422h05Business WireZai Lab Announces First Quarter 2024 Financial Results and Recent Corporate UpdatesNASDAQ:ZLABZai Lab Ltd
15/04/202413h30Business WireZai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024NASDAQ:ZLABZai Lab Ltd
11/04/202413h30Business WireZai Lab Statement on Executive Management Team’s Agreement on Share ActivitiesNASDAQ:ZLABZai Lab Ltd
02/04/202413h30Business WireZai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology ProgramsNASDAQ:ZLABZai Lab Ltd
01/04/202413h30Business WireZai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...NASDAQ:ZLABZai Lab Ltd
27/03/202414h29Business WireZai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung CancerNASDAQ:ZLABZai Lab Ltd
14/03/202400h05Business WireZai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid TumorsNASDAQ:ZLABZai Lab Ltd
06/03/202422h01Business WireZai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)NASDAQ:ZLABZai Lab Ltd
06/03/202413h30Business WireZai Lab Announces Participation in March Investor ConferenceNASDAQ:ZLABZai Lab Ltd
04/03/202422h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
27/02/202422h20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ZLABZai Lab Ltd
27/02/202422h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZLABZai Lab Ltd
27/02/202422h05Business WireZai Lab Announces Full-Year 2023 Financial Results and Recent Corporate UpdatesNASDAQ:ZLABZai Lab Ltd
08/02/202422h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZLABZai Lab Ltd
25/01/202422h15Business WireZai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024NASDAQ:ZLABZai Lab Ltd
10/01/202423h12Business WireZai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLCNASDAQ:ZLABZai Lab Ltd
04/01/202401h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
04/01/202401h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
04/01/202401h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
03/01/202421h50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ZLABZai Lab Ltd
 Showing the most relevant articles for your search:NASDAQ:ZLAB

Kürzlich von Ihnen besucht

NYSE
FTV.PRA
Fortive Corporation
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten